Here's how much Ozempic and similar drugs have soared in popularity since 2018
The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and 2022, with annual spending surging from $1.6 billion to $5.8 billion.
The findings were reported by MedPageToday on Tuesday, citing a new study published in the Annals of Internal Medicine.
Researchers analyzed data from the Centers for Disease Control and Prevention's (CDC) National Health Interview Survey (NHIS), using an unweighted sample of 90,000 adults. They found that the percentage of U.S. adults without diabetes filling at least one GLP-1 prescription increased from 0.1% in 2018 to 0.4% in 2022 — representing approximately 854,728 adults. By comparison, about 5.1 million adults with type 2 diabetes filled a prescription for the drugs that same year, according to a separate study.
The total number of people taking GLP-1 treatments today could also be much higher. In aMay 2024 survey of 1,479 U.S. adults, about 12% said they'd taken a GLP-1 agonist, and almost one third said they'd heard 'a lot' about these treatments, according to the health policy non-profit KFF.
GLP-1s are a class of drugs that have been used for decades to treat diabetes. They mimic a hormone that helps regulate blood sugar and can also suppress appetite. But a newer generation of these drugs — such as Novo Nordisk's Ozempic and Eli Lilly's (LLY) Mounjaro — has fueled a surge in demand. Unlike older versions, which required daily doses, these newer medications are injected just once a week. Demand skyrocketed even further after the drugs were approved for weight loss. Novo Nordisk's Wegovy received approval to treat obesity in 2021, followed by Eli Lilly's Zepbound in 2023.
By 2022, 65% of GLP-1 users without diabetes were on semaglutide — the active ingredient in Ozempic and Wegovy. Most GLP-1 users without diabetes were female (64%) and white (73%), with an average body mass index (BMI) of 35.7, classifying them as obese.
The blockbuster success of these drugs has transformed Novo Nordisk and Eli Lilly into two of the world's most valuable pharmaceutical companies. Novo Nordisk's total revenue rose 26% in 2024 to $40.5 billion, while Eli Lilly saw a 32% jump, reaching $45 billion.
For the latest news, Facebook, Twitter and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 minutes ago
- Business Wire
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), regardless of prior dengue exposure. Recruitment for the trial has begun, and the first participants are now enrolling in Singapore. 'Approximately half of the world's population live in areas with a risk for dengue, making it a serious public health threat,' said Dr. Paula Annunziato, senior vice president, infectious diseases and vaccines, global clinical development, Merck Research Laboratories. 'The initiation of the MOBILIZE-1 study, the first Phase 3 trial in our clinical development program, marks a key milestone in our work to help address this widespread mosquito-borne disease. If successful, V181 could provide an important single-dose option for at risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe.' Merck is committed to research and innovation that aims to help protect the millions of people at risk for dengue virus infection and is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is a significant health threat. About MOBILIZE-1 (NCT07013487) MOBILIZE-1, also known as V181-005, is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety, immunogenicity and efficacy of V181, an investigational vaccine for the prevention of dengue disease. The study aims to enroll approximately 12,000 healthy individuals 2 to 17 years of age who will be randomized to receive either a single dose of V181 or placebo. The study is planned to include more than 30 trial sites in dengue endemic areas in the Asia-Pacific region, including Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam. The primary endpoints of the study are safety and efficacy of a single dose of V181 in preventing symptomatic virologically confirmed dengue (VCD) of any severity, due to any of the four dengue serotypes, regardless of prior dengue exposure. The key secondary efficacy endpoint is evaluating a single dose of V181 in preventing symptomatic VCD of any severity due to each of the four dengue serotypes, regardless of prior dengue exposure. Additional secondary endpoints include evaluating a single dose of V181 in preventing symptomatic VCD with warning signs, severe VCD and hospitalization. For more information on the trial, visit About V181 V181 is a live attenuated quadrivalent vaccine currently being investigated for the prevention of dengue disease caused by any of the four dengue virus types (DENV-1, DENV-2, DENV-3, and DENV-4). V181 is designed to be a single-dose vaccination and is being studied in individuals to provide protection against dengue, including severe forms, whether the individuals have been previously infected with the dengue virus or had no prior infections. About Dengue disease Dengue disease is one of the fastest growing mosquito-borne diseases that affects not just the health but often the economic stability of communities across the globe. It is a rapidly emerging cause of serious and sometimes debilitating illness in tropical and subtropical countries. With approximately half of the world's population, or four billion people, at risk for dengue disease, it represents a critical public health challenge. Globally, around 105 million dengue viral infections occur annually, with approximately 50-60 million being symptomatic on average per year. While the majority of infections are uncomplicated, serious illness caused by dengue can be severe and lead to death (on average, ~4-11 million cases result in hospitalizations per year and there is an average annual incidence of ~29,000 dengue-related deaths worldwide). Symptoms of mild dengue fever may include a high fever, a rash and muscle and joint pain. Dengue fever might evolve to severe dengue, formerly known as dengue hemorrhagic fever, which can cause severe bleeding, a sudden drop in blood pressure, and in rare cases, death. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (
Yahoo
22 minutes ago
- Yahoo
Goodbye, dad bod: Weight loss medications are changing fathers' physiques — and their relationships with their kids.
Neal Bland has done Ironman competitions and marathons. He's given countless personal training sessions over the course of his life and has always prided himself on staying in shape, especially given that obesity runs in his family. But by age 52, time and genetics had begun to catch up with Bland (who asked that we not use his real last name for privacy reasons). His blood pressure and blood sugar were climbing, his body mass index was hovering in the low 30s, and his joints were aching. Then, during a photo shoot with his wife last year, the photographer told Bland he 'looked good for a dad bod.' Bland knew the photographer had 'meant it as a compliment,' he tells Yahoo Life, 'but it really stuck.' He was still maintaining a rigorous diet and exercise regimen at the time, but it wasn't working for him. So, in March of 2024, he started on the GLP-1 medication tirzepatide. He's lost 45 pounds in a phase of his life he's dubbed his 'dad bod reboot.' Let's be clear: There's nothing wrong with a dad bod. In fact, the expectation for men to have chiseled abs — at any point, but especially in middle and older age — can be harmful. But for the 38% of American dads who are obese, their bodies may be putting them at risk of type 2 diabetes, heart disease and other potentially life-threatening medical conditions. Some of these fathers have started taking GLP-1 weight loss medications, a decision that can bring about not just changes to their 'bods' and health indicators, but also to their lives as parents. We spoke to some of them about what it's like to be a dad, minus their former bods. Thirty-seven-year-old father of two Noah Wiggins is taking his nursing board exams and looking forward to beginning his new career in health care. 'But I looked in the mirror and thought, I can't expect patients to be healthy and maintain a healthy weight if I can't,' he tells Yahoo Life. Plus, Wiggins loves coaching his children's sports teams, but he found himself getting winded and sore when he tried to demonstrate athletic skills for the kids. While he could shed pounds for a time with the help of various diets, he couldn't maintain a healthy weight long-term. So Wiggins talked to his own health care provider, who agreed that GLP-1 medication could be a good option for him. He started taking Zepbound in January 2024. The medication, along with the support of his two children, has helped him lose more than 80 pounds since then. 'As I started to lose weight and get more active, they started making comments and encouraging me to make healthy food choices … without judgment,' says Wiggins. His daughter, who is about to turn 16, has been especially vocal, keeping Wiggins accountable when he picks up an unhealthy snack or tries to flake on going to the gym. 'I've had to fight the urge to say, 'I'm the parent, I'll go when I want to,'' says Wiggins. But ultimately, he's grateful for the tough-loving support from his kids. 'I think it's been a growing moment for them and for me,' he says. Wiggins's children have also noticed that he has more energy and can just be more fully present for them. Despite his progress, Wiggins still struggles with his body image. Like others that Wiggins has spoken to within the GLP-1 community, he half-expected that once the scale reached a certain number, he would feel satisfied with his body and appearance. 'But I don't know anyone who actually hits that number and feels like that,' he says. 'I look in the mirror and am happy with how I look and especially how I feel, but body dysmorphia is a real thing, and a lot of times you don't know you have it until you've lost weight.' At his lowest weight, Wiggins was tempted to lose another 20 pounds to make his reflection match the idealized version of himself in his mind, but he knew that would have put him below a healthy weight. That's when Wiggins realized that it wasn't about losing more weight. He needed to make a conscious effort to improve his mental health and confidence to help him feel content in his own skin. It's an important lesson that he wants his children to learn: how to 'be comfortable in your body, but balance that with good health,' Wiggins says. He's pushed himself to talk more openly with his kids about his own journey toward striking that balance. 'The best thing to do was just have more conversations with them about all of that, and they'll actually take the lead on those conversations once you start them.' Twenty years ago, when Ryan Rasmussen and his wife, AnnaLyn, were young newlyweds, they wanted desperately to start a family. After three years of trying, AnnaLyn got pregnant with quadruplets. But tragedy struck: None of the four babies survived more than about an hour after birth. The Rasmussens managed to pick up the pieces of their shattered hearts and eventually went on to have four children, born individually. But even as someone moves on, grief can linger in the body, wreaking havoc. For Rasmussen, the loss of his newborns quietly ate at him and, in turn, Rasmussen now recognizes he ate to cope with his grief. He reached nearly 300 pounds, he told Yahoo Life for our series On My Weigh. For those intervening 20 years, Rasmussen tried the Atkins diet and various other low-carb eating plans. He'd lose a little weight, then gain back as much or more. In the meantime, his family stayed active and went on ski trips. 'Annalyn is a marathon runner, and she's kept [the kids] in shape, but I think they've probably worried about me,' says Rasmussen. He tried to join their athletic activities, but skiing and hiking were hard on his overburdened joints. Two of his sisters, who also struggled with their weight, found success with GLP-1 medications. Impressed with their progress, Rasmussen tried the new class of weight loss drugs too. Within a year, he dropped 80 pounds. 'Being there for my family was the goal,' he says. Not only can Rasmussen now join the family ski trips, but hiking and spending time outdoors are day-to-day ways he bonds with his kids. His weight loss 'has definitely allowed us as a family to do more healthy activities,' Rasmussen says. Plus, his good habits have rubbed off on his children. Desserts, once a staple, are reserved for special occasions, and the household's midnight snacking has all but disappeared. Rasmussen's new body has also allowed him to get back in touch with his fashion sense. 'I like to look good and dress well, but when you're big, [that's] difficult,' he says. Now that he's lost weight, 'being able to dress with purpose in the morning has probably been one of the best things for me and my mental health,' says Rasmussen. And he's not the only one who's noticed his new look. One of his daughter's friends used the viral 'hear me out' cake trend on TikTok as an excuse to show some appreciation for Rasmussen. 'She said, 'hear me out, but Charlie's dad is attractive,'' Rasmussen explains. 'But [Charlie] was a good sport, she laughed about it.' Bland's now adult children grew up knowing him as the ultra-fit dad, who was always on the go for his job as a pharmaceutical researcher, or hitting the gym to train for his next big event. But he was always fighting against his genetics. 'I come from a long line of fluffy people,' Bland says. He spent his own childhood watching his mother constantly watch her weight. Despite avoiding smoking and drinking and maintaining a reasonably healthy diet, she eventually had to have both of her knees and one hip replaced and also suffered a stroke, 'all of which can be attributed to [extra] weight on your frame,' says Bland. Recognizing his family's propensity to obesity was part of what drove Bland to be so disciplined. 'But my genetics eventually outran my lifestyle,' he says. Even with the same routines in place, Bland gained weight in his early 50s, saw his A1C and blood pressure rise, and had inflammation in his hips and knees. And Bland admits that vanity was also a factor. The shirtless man in his vacation photos no longer looked like the version of himself he expected to see. 'I gained about 35 pounds in 10 years; it was the classic 'man-o-pause,'' he says. Though he didn't meet the clinical qualifications for brand-name GLP-1 medications, Bland tried compounded tirzepatide, suspecting that it would not only help him keep weight off but also reduce the inflammation in his joints. Once he started the medication, 'it was literally like somebody flipped a switch,' says Bland. The food noise (constant, intrusive thoughts about food) disappeared. He no longer ate just because he was bored. The joint pain was barely noticeable, and his workout recovery time improved. He also started to look more like himself in gym selfies. Bland didn't initially tell his children that he was taking GLP-1 medications. But one of his adult sons noticed that Bland was looking pretty shredded in some of his photos; in fact, he was a bit concerned. He told his father, 'You've lost so much weight and went from really fluffy to really not. Are you sure you're not ... taking PEDs,' meaning performance-enhancing drugs, recalls Bland. Though Bland, now 53, has been taking testosterone replacement therapy for years, that and the GLP-1 have allowed him to return to the weight and energy levels of his younger years. And he's now switched to a very low maintenance dose of tirzepatide to make sure he doesn't lose too much weight. 'It's been a little bit of a return to what they were used to when they were kids,' he says of his new — or, maybe more accurately, restored — bod. 'And I feel like I'm back to the person that my wife married,' Bland adds.
Business Wire
an hour ago
- Business Wire
ENYO Pharma Announces Completion of Series C Financing With Vesalius Biocapital and Continued Progress of Its ALPESTRIA-1 Clinical Phase 2 Study in Alport Syndrome Patients
LYON, France--(BUSINESS WIRE)--ENYO Pharma ('ENYO'), a clinical-stage biotechnology company focused on developing FXR agonists for the treatment of severe kidney diseases, today announced the smooth continuation of its Phase 2 ALPESTRIA-1 trial in 26 Alport syndrome patients. The topline results from the trial are on track for the fourth quarter of 2025. In parallel, ENYO has finalized its Series C financing round with a €6 million investment from Vesalius Biocapital IV, bringing the total Series C raise to €32 million. The ongoing ALPESTRIA-1 study evaluates Vonafexor, a highly selective and oral FXR agonist, in patients with Alport syndrome, a rare genetic kidney disease with no approved therapy. The trial involves a 24-week ascending doses regimen followed by a 12-week off-treatment observation period. ALPESTRIA-1 was launched mid 2024 in 4 countries (US, F, SP and D) following Orphan Drug Designation from both the FDA and EMA. The new funding from Vesalius Biocapital IV extends ENYO's cash runway through the second half of 2026 and enables the initiation of two new clinical programs: A proof-of-concept trial in patients with Chronic Kidney Disease (CKD) grade 3 and concurrent F2/F3 MASH, building on the promising renal results from the previous Phase 2 LIVIFY clinical study; A PK/PD head-to-head comparison of Vonafexor and its analog EYP651 in healthy subjects. In addition, ENYO will continue to expand its preclinical portfolio, notably in Autosomal Dominant Polycystic Kidney Disease (ADPKD), where the Vonafexor franchise could offer a novel and disease-modifying approach. ' We are pleased with the continued progress of ALPESTRIA-1 and honored to welcome Vesalius Biocapital to our investor syndicate and Dr. Jean-Christophe Renondin as new Board member,' said Dr. Jacky Vonderscher, CEO of ENYO. ' This additional investment will allow us to accelerate the development of our FXR agonist pipeline in both rare and more prevalent kidney diseases. We share a common belief with Vesalius in the transformative potential of Vonafexor and EYP651 for patients suffering from inflammation- and fibrosis-driven renal conditions.' ' Vesalius Biocapital is excited to support ENYO as it progresses into the next phase of clinical development for Vonafexor and its analog EYP651, ' commented Dr. Jean-Christophe Renondin, Managing Partner at Vesalius Biocapital IV. ' There is an immense need for new treatments in kidney conditions such as Alport Syndrome and CKD. We believe Vonafexor has the potential to help these patients and make a meaningful impact on their lives. I look forward to working with ENYO's excellent leadership team to advance this promising therapeutic candidate.' About ENYO Pharma: ENYO is a clinical-stage biopharmaceutical company headquartered in Lyon (France) and developing proprietary drug candidates to improve quality of life and avoid end stage renal disease and dialysis/transplantation for patients with rare and common kidney diseases. Since its inception ENYO collected extensive phase I/II clinical data through nine completed clinical studies with ca. 400 subjects. ENYO is supported by a strong syndicate of global investors: OrbiMed, Morningside, AndEra, BPIFrance (InnoBio and Large Venture), Sofinnova Partners and Vesalius). For more information: ENYO Pharma About Vesalius Biocapital: Vesalius is a specialist life sciences venture capital investor, investing in companies in later stage companies in drug development, medical device diagnostic and e-health since 2007. Vesalius Biocapital IV, launched in June 2023, targets first and best-in-class European life science companies in drug development and digital health. Its investment portfolio is well balanced between drug development and non-drug development investments and committed to providing capital to science-backed innovation and ambitious entrepreneurs. The team is based in Europe to explore investment opportunities and valuation potential for the portfolio. Managing Partners include Guy Geldhof, Dr Jean-Christophe Renondin and Stéphane Verdood.
